Vietnam Medical and Pharmaceutical Investment Joint Stock Company

As of December 31, 2022, Vietnam Medical and Pharmaceutical Investment Joint Stock Company carries a market capitalization of 343.13B, placing it among publicly traded companies globally. Its enterprise value stands at 211.09B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of December 31, 2022, Vietnam Medical and Pharmaceutical Investment Joint Stock Company has 112.50M shares outstanding.

These figures are as of December 31, 2022. The price-to-sales ratio is 0.72, and the price-to-book ratio stands at 0.78.

As of December 31, 2022, Vietnam Medical and Pharmaceutical Investment Joint Stock Company trades at an EV/EBITDA multiple of 4.46 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.44 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 211.09B versus a market cap of 343.13B, with the gap driven by net debt and cash on the balance sheet.

As of December 31, 2022, Vietnam Medical and Pharmaceutical Investment Joint Stock Company maintains a current ratio of 2.69, meaning it holds 2.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 9.74, indicating elevated leverage, while an interest coverage ratio of 9.96 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended December 31, 2022, Vietnam Medical and Pharmaceutical Investment Joint Stock Company posted a negative return on equity (ROE) of -2.46, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -1.94, reflecting losses generated across the asset base. The company generates approximately 2.39B in revenue per employee across its workforce of 203.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 4.62 indicates how many times Vietnam Medical and Pharmaceutical Investment Joint Stock Company sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended December 31, 2022, Vietnam Medical and Pharmaceutical Investment Joint Stock Company recorded 1.22B in income tax expense. The company reported a pretax loss of -10.80B and -11.96B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Vietnam Medical and Pharmaceutical Investment Joint Stock Company's stock has declined approximately 65.24% over the past 52 weeks. The 50-day moving average sits at 2,836.80, while the 200-day moving average is 3,968.60.

Over the twelve months ended December 31, 2022, Vietnam Medical and Pharmaceutical Investment Joint Stock Company generated 485.11B in revenue and converted that into -11.96B in net income, yielding earnings per share of -104.59. EBITDA reached 47.31B, while operating income came in at -23.11B.

As of December 31, 2022, Vietnam Medical and Pharmaceutical Investment Joint Stock Company holds 175.21B in cash and equivalents against 42.98B in total debt, resulting in a net debt position of -132.23B. Total book value stands at 441.09B, with working capital of 240.26B providing operational flexibility.

Vietnam Medical and Pharmaceutical Investment Joint Stock Company produced 68.02B in operating cash flow over the twelve months ended December 31, 2022. After subtracting -32.32B in capital expenditures, free cash flow totaled 35.70B - equivalent to 310.68 per share.

Over the twelve months ended December 31, 2022, Vietnam Medical and Pharmaceutical Investment Joint Stock Company posted a gross margin of 19.10, reflecting its pricing power and cost economics. The operating margin of -4.76 and net profit margin of -2.47 provide insight into operational efficiency.

These figures cover the twelve months ended December 31, 2022. Free cash flow yield stands at 10.19, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 8.00, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Vietnam Medical and Pharmaceutical Investment Joint Stock Company shareholders.

Vietnam Medical and Pharmaceutical Investment Joint Stock Company's most recent stock split took place on October 31, 2014.

As of December 31, 2022, Vietnam Medical and Pharmaceutical Investment Joint Stock Company has an Altman Z-Score of -0.04, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.